drugset / Trial / NCT03202784

A Relative Bioavailability Study of Two Formulations of BCX7353

NCT03202784

Phase 1 Completed 24 enrolled BioCryst Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open-label, randomized study to investigate the relative bioavailability of two formulations of BCX7353 and to determine if there is a food effect

Timeline

Start
2017-02-27
Primary completion
2017-08-01
Completion
2017-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject berotralstat Small molecule

Indications